Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $15000.0.

  • Ligand Pharmaceuticals' Capital Expenditures changed N/A to $15000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.7 million, marking a year-over-year decrease of 19644.51%. This contributed to the annual value of $1.8 million for FY2024, which is 4828.17% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Capital Expenditures stood at $15000.0 for Q3 2025.
  • Ligand Pharmaceuticals' Capital Expenditures' 5-year high stood at $74.9 million during Q2 2024, with a 5-year trough of -$73.2 million in Q4 2024.
  • In the last 5 years, Ligand Pharmaceuticals' Capital Expenditures had a median value of $1.6 million in 2021 and averaged $1.8 million.
  • Over the last 5 years, Ligand Pharmaceuticals' Capital Expenditures had its largest YoY gain of 3679408.87% in 2024, and its largest YoY loss of 1764892.09% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Capital Expenditures (Quarter) stood at $2.2 million in 2021, then dropped by 2.92% to $2.1 million in 2022, then crashed by 80.43% to $417000.0 in 2023, then tumbled by 17648.92% to -$73.2 million in 2024, then surged by 100.02% to $15000.0 in 2025.
  • Its last three reported values are $15000.0 in Q3 2025, $214000.0 for Q2 2025, and $214000.0 during Q1 2025.